Recommendations on multiple testing adjustment in multi-arm trials with a shared control group by Howard, Dena R. et al.
1Recommendations on multiple testing adjustment in multi-arm trials with a shared
control group
Dena R Howard1, Julia M Brown1, Susan Todd2, Walter M Gregory1
1Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United
Kingdom
2Department of Mathematics and Statistics, University of Reading, Reading, United
Kingdom
Correspondence to: Dena Howard
Author contact details:
Dena Howard
Leeds Institute of Clinical Trials Research
University of Leeds
Leeds
LS2 9JT
United Kingdom
Email: D.R.Cohen@leeds.ac.uk
Tel: 0113 343 1475
Fax: 0113 343 1471
2Recommendations on multiple testing adjustment in multi-arm trials with a shared
control group
Short Title
Recommendations on multiple testing adjustment in multi-arm trials
Abstract
Multi-arm clinical trials assessing multiple experimental treatments against a shared
control group can offer efficiency advantages over independent trials through assessing
an increased number of hypotheses. Published opinion is divided on the requirement for
multiple testing adjustment to control the familywise type-I error rate (FWER). The
probability of a false positive error in multi-arm trials compared to equivalent
independent trials is affected by the correlation between comparisons due to sharing
control data. We demonstrate that this correlation in fact leads to a reduction in the
FWER, therefore FWER adjustment is not recommended solely due to sharing control
data. In contrast, the correlation increases the probability of multiple false positive
outcomes across the hypotheses, although standard FWER adjustment methods do not
control for this. A stringent critical value adjustment is proposed to maintain equivalent
evidence of superiority in two correlated comparisons to that obtained within
3independent trials. FWER adjustment is only required if there is an increased chance of
making a single claim of effectiveness by testing multiple hypotheses; not due to
sharing control data. For competing experimental therapies, the correlation between
comparisons can be advantageous as it eliminates bias due to the experimental therapies
being compared to different control populations.
Keywords
multiple testing; multi-arm clinical trial; familywise error rate; type-I error; multiplicity;
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41. Introduction
A typical confirmatory two arm trial would usually compare an experimental treatment
against the current standard within the population of interest. For several reasons, it is
advantageous to conduct multi-arm trials, in which a number of experimental treatments
are compared to the current standard. Firstly, such trials are more efficient since they
use the data collected on the control group more than once so fewer patients are
required. Secondly, trial set-up times and costs can be reduced over running separate
trials. Finally, increasing the number of experimental arms increases the chance of
finding a successful treatment1.
When testing a hypothesis in a phase III clinical trial, the chance of a false positive
result, known as the type-I error, is required to be stringently controlled. The convention
is to set this error, usually denoted by α, to be no greater than 5% by setting the one-
sided p-value to <0.025. If more than one hypothesis is to be tested within a set, or
family, of hypotheses, the chance of a false positive conclusion occurring anywhere
within that set is known as the familywise error rate (FWER). That is, the FWER is the
probability of at least one false positive conclusion being declared anywhere within a
family of hypotheses.
5There are conflicting viewpoints within the literature on whether the relevant errors to
control in the case of multi-arm trials are the individual type-I errors for each
hypothesis, known as the pairwise error rates, or the overall FWER for all hypotheses
combined. The crux of the issue is how ‘family’ should be defined; whether all
hypotheses belong to a family simply because they share a protocol and control group,
or whether a family is a set of hypotheses that are related in that they contribute towards
a single claim of effectiveness.
The literature on requirement for multiplicity adjustment is often based on philosophical
opinions, rather than statistical theory considering the actual effect on the type-I error
rates of using a shared control group compared to running independent trials. Some
literature, including a points to consider document from the European Agency for the
Evaluation of Medicinal Products (EMEA)2, advocates strong control of the FWER for
confirmatory claims because the hypotheses are being tested within a single experiment,
regardless of the relatedness of the hypotheses3, 4. Others argue that adjustment is not
required in all cases, particularly although not exclusively, where the experimental arms
do not contribute towards a single claim of effectiveness, because the design is
essentially just running a number of different trials5-9. Although most of the literature
agrees that the need for adjustment should be considered and justified in each case,
including the International Conference on Harmonisation (ICH) E9 guidance of
6Statistical Principles for Clinical Trials10, no literature has been found to give
comprehensive guidance from a quantitative, rather than philosophical, perspective on
which situations require type-I error adjustment and which do not.
Discussion points from the Statisticians in the Pharmaceutical Industry multiplicity
expert group state that “the concern with multiplicity is that, if it is not properly
handled, unsubstantiated claims for the effectiveness of a drug may be made as a
consequence of an inflated rate of false positive conclusions”11. In this manuscript, we
therefore break down and quantitatively investigate the aspects of a multi-arm trial that
affect the chance of different types of false positive errors on a claim of effectiveness in
order to make informed recommendations on the need for adjustment. We begin by
providing examples in Section 2, and describing the background to multiplicity
concerns in multi-arm trials in Section 3. In Section 4 we investigate the effect of the
shared control data on the chance of type-I errors. Section 5 shows the probabilities of
type-I errors after applying common multiplicity adjustment methods in the case of
shared control data, and we compare these to the errors had the hypotheses been
assessed within independent trials. In Section 6 we suggest a correction to control for
the increased probability of multiple type-I errors that advantage the experimental
treatment, which may be necessary where more than one superior outcome within the
7protocol could inform the same claim of effectiveness. The paper concludes with a
discussion in Section 7.
2. Motivational examples
Three examples of multi-arm trials with different types of design and varying levels of
relatedness between the hypotheses are considered in this article.
2.1 MRC COIN
The phase III MRC COIN trial12 in previously untreated patients with colorectal cancer
had three-arms and two primary hypotheses. The control treatment was chemotherapy
with oxaliplatin and fluoropyrimidine (OxFP) given continuously (arm Z). One
experimental arm included an additional therapy cetuximab to OxFP (arm A), and the
other assessed the chemotherapy OxFP given intermittently (arm B). Patients were
randomised to the three treatment arms with a 1:1:1 ratio, and the trial objective was to
assess a difference in overall survival at two years for each of the comparisons, arm A
vs Z and arm B vs Z.
2.2 AMAGINE-1
8The phase III AMAGINE-1 trial (clinicaltrials.gov identifier: NCT01708590) was run
by Amgen / AstraZeneca from 2012 to 2015. The trial assessed the safety and efficacy
of brodalumab taken every two weeks via subcutaneous injection at two doses (140 mg
or 210 mg) compared with placebo in patients with moderate-to-severe plaque psoriasis.
The primary hypotheses concerned the efficacy of brodalumab compared to placebo, as
assessed by Static Physician Global Assessment (sPGA) score and improvement in
Psoriasis Area and Severity Index (PASI) at 12 weeks.
2.3 Myeloma XI+ Intensive
The Myeloma XI Intensive trial (ClinicalTrials.gov Identifier: NCT01554852) at the
University of Leeds opened to recruitment in 2010, comparing the current standard
therapy CTD (cyclophosphamide, thalidomide and dexamethasone) with CRD
(cyclophosphamide, lenalidomide and dexamethasone) in terms of progression-free
survival (PFS) in newly diagnosed patients with Multiple Myeloma. It was anticipated
that recruitment would take up to four years, with the required number of events
occurring within three years after the close of recruitment. During recruitment, early
evidence suggested a new therapy, carfilzomib, added to the existing CRD regime
(CCRD) might improve efficacy. Since it was of interest to assess CCRD as soon as
possible, the follow-on Myeloma XI+ intensive trial was designed without waiting for
9the results of the original trial, and opened to recruitment in 2013 following on
seamlessly from Myeloma XI. The Myeloma XI+ trial therefore compared the
experimental therapy CCRD to the current standard control CTD and the previous
experimental therapy CRD at a 2:1:1 randomisation in order to protect the trial in the
case that CRD was found superior and superseded CTD as the standard therapy before
the amended trial had completed and reported.
3. Background to multiplicity concerns in multi-arm trials
3.1 Shared control data
If two experimental treatments, say A and B, are to be compared against the current
standard, say Z, in independent trials, it is accepted that there is no requirement for
multiple testing adjustment. If these two hypotheses are instead assessed within the
same protocol, where the data remain entirely independent and non-overlapping with
separate control groups Z1 and Z2, and the hypotheses are both powered separately and
appropriately (figure 1a), it would be difficult to argue for multiple testing adjustment
since there is no multiple use of any data. The sharing of a protocol or even a
randomisation system in this case does not affect the probability of an error over that for
independent trials. Westfall et al.13 report that it may be plausible that multiplicity
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problems due to sharing a protocol could result from “selection effects” such as the
method of assessment of the primary endpoint. However, this could just as easily occur
in two independent trials led by the same trials team. Therefore it would seem that there
is no additional reason for multiplicity concerns due to simply sharing a protocol, when
separate pieces of confirmatory evidence are not required to be obtained from distinct
teams.
[Insert Figure 1a]
Figure 1a. Illustration of two separate hypotheses being tested within the same
protocol. There is no overlap of the use of patients, so the questions are entirely
independent. R denotes the point of randomisation.
A trial of the design displayed in figure 1a may not make practical sense where the
eligibility criteria and control group for both experimental treatment comparisons are
the same. Efficiency can be greatly improved by comparing both experimental arms to
the same group of control patients. If the treatment difference being sought is the same,
then utilising a single control group offers a saving of 25% of the trial sample size for
an even allocation ratio (figure 1b).
[Insert Figure 1b]
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Figure 1b. Illustration of a multi-arm design where two separate hypotheses are being
asked within the same protocol and sharing the same control patients. R denotes the
point of randomisation.
For the design shown in figure 1b, the hypotheses can be addressed separately and can
both be adequately powered. Given the logic that the use of the same protocol does not
cause multiplicity concerns over the same hypotheses being tested in independent trials,
the difference is around the shared use of the control data. The comparisons are no
longer independent, but are correlated based on the shared comparator group14. The
impact of this correlation can be formally quantified to inform the necessary adjustment
so that the chances of errors do not exceed those for independent trials. Proschan et al.15
examine the effects of treatments being compared to a control within the same trial
compared to independent trials, “in terms of the different distributions of the number of
Type-I errors and power”. Senn16 considers the conditional probability of a type-I error
under the null hypothesis of “concluding that a given dose is significant given that all
other doses tested to date are significantly different from placebo” when comparing
multiple doses against a placebo, as an alternate way of thinking about the probability of
multiple errors within a family. He notes that “even where the probabilities of making at
least one type-I error are controlled, conditional error rates may not be”, but does not
make recommendations for multiple testing adjustment based on this. Very little
12
literature has been published assessing the effect of shared control data on the
probabilities of type-I errors over those in independent trials, and this effect is rarely
considered when assessing the requirement for multiplicity adjustment in multi-arm
trials. Extending the work of Proschan et al. we further investigate the effect of
correlation due to shared control data in detail within this manuscript.
3.2 Increased chance of making a single claim of effectiveness for a therapy
Section 3.1 highlights that a key statistical implication of running a single multi-arm
trial compared to separate trials is due to multiple use of shared control data. However,
another factor that could increase the chance of a false conclusion over that for
independent trials is the ability to test more hypotheses than would otherwise have been
assessed. The necessity for adjustment in this case is a largely philosophical, rather than
necessarily statistical, argument that has been well addressed in the literature, albeit
with varying opinions, and needs to be considered and justified on a trial-by-trial basis4-
8.
On reviewing the literature, our opinion is that if the hypotheses contribute towards a
single claim of effectiveness, for example because they assess different doses of the
same therapy with any success leading to promotion of that therapy, the hypotheses are
likely to be considered a ‘family’ and therefore FWER adjustment may be required. If
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the hypotheses inform different claims of effectiveness, for example because they are
assessing different experimental therapies, FWER control is likely to be an unnecessary
penalty5, 6. This does not contradict ICH E9 ‘Statistical Principles for Clinical Trials’10,
which states that “adjustment should always be considered, and the details of any
adjustment procedure or an explanation of why adjustment is not thought to be
necessary should be set out in the analysis plan.” Hung and Wang 17 discuss defining “a
relevant family of hypotheses for which the type-I error needs to be properly
controlled”, and recommend a “clinical decision tree”, determined in advance, to decide
what aspects need to be protected from type-I error inflation. The decision on
adjustment due to assessing multiple hypotheses should be made at the design stages for
each trial and documented with full justification. This important consideration is
incorporated into the recommendations on adjustment in multi-arm trials given in
Section 7.
4. The effect of correlation due to shared control data
As noted above, whilst the increased chance of making a single claim of effectiveness
based on multiple hypotheses within a trial has been widely discussed in the literature,
the effect of correlation due to multiple use of the shared control data has been less well
addressed and does not appear to be widely understood, and therefore forms the main
focus of this manuscript.
14
We begin by stating some key definitions before exploring the quantification of the
effect of the shared control data.
4.1 Definitions of error regions
In two independent hypothesis tests, such as illustrated in the trial design given in figure
1a, the null hypothesis H0A assesses therapy A against Z1, with test statistic ஺ܺ, and the
null hypothesis H0B assesses therapy B against Z2, with test statistic ܺ஻, each with a
two-sided significance level of 0.05. It can be assumed that the test statistics for each
comparison follow a normal distribution when sample sizes are reasonable.
Figure 2 illustrates the joint density for the standardised test statistics in this setting,
based on the probability density function of the standardised bivariate normal
distribution with no correlation, since the tests are independent. The rejection regions
for the hypothesis tests are the shaded areas around the outside of the square, as
described by Fernandes and Stone14.
The probability of falling within just one of the four shaded rejection regions along the
length of the edges is 2.5%. That is, the probability of concluding that either therapy is
15
either falsely inferior or falsely superior to its control therapy is 2.5%. The darker
shaded corner regions represent the probability that both hypotheses have false positive
outcomes, that is there are two type-I errors.
[Insert Figure 2]
Figure 2. Rejection regions for two independent comparisons plotted on orthogonal
axes, with the standardised test statistic for the null hypothesis H0A being displayed
horizontally, and H0B displayed vertically.
The amount of false positive error that falls in different shaded regions within figure 2
may have different implications depending on the goals of the trial. We have therefore
defined various types of false positive error below, and these will first be quantified in
the case of independent comparisons before exploring the case where there is shared
control data.
Familywise Error Rate (FWER):
Recall that the FWER is the overall probability of at least one false positive conclusion
anywhere within a defined set of trial hypotheses. It can be seen from figure 2 that in the
case of two independent comparisons and a two-sided significance level of 0.05, if we
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consider the two comparisons as a family, the FWER is equal to the total shaded region.
This can be calculated by the sum of the four shaded regions around the edges, minus
the darker shaded regions that are double counted in the four corners.
ܨܹ ܧܴ = (4 ∗ 0.025) − (4 ∗ 0.025ଶ) = 0.0975
Note that the FWER can easily be confirmed for independent comparisons, as it can be
described using a binomial distribution since each null hypothesis has a binary outcome
associated with it. Define Y to be the random variable associated with the event that a
type-I error occurs. In the independent case, with k comparisons and a probability α of 
finding a significant difference, the probability of exactly y type-I errors across the k
comparisons (y = 1,…,k) can be expressed as:
ܲ(ܻ = ݕ) = ൬݇
ݕ
൰ߙ௬(1 − ߙ)௞ି௬
Since the FWER is the probability of at least one error,
ܨܹ ܧܴ = ݌(ܻ > 0) = 1 − ݌(ܻ = 0) = 1 − (1 − ߙ)௞
So, with two independent comparisons and α = 0.05 for each as illustrated in figure 2, 
the FWER is 0.0975, as expected.
Family Multiple Error Rate (FMER):
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A second type of false positive error can be defined as the chance of multiple false
positive findings across a family of hypotheses, which we call the Family Multiple
Error Rate (FMER).
The overall error that exists in any family of hypotheses will always equal the sum of
the errors for each hypothesis. With a family of two (null) hypotheses H0A and H0B
respectively relating to the comparisons of therapies A and B with control, and α=0.05
for each, the total error will be 0.1. By probability theory:P(H଴୅) + P(H଴୆) = P(H଴୅ ∪ H଴୆) + P(H଴୅ ∩ H଴୆)P(H଴୅) is the probability of a type-I error for the null hypothesis H0A.
ܲ(H଴୆) is the probability of a type-I error for the null hypothesis H0B.P(H଴୅ ∪ H଴୆) is the overall chance of a type-I error, i.e. the FWER.P(H଴୅ ∩ H଴୆) is the chance of more than one error occurring from the same pair of null
hypotheses, which is the FMER.
In figure 2, the FMER is represented by the sum of the probabilities in the four dark
shaded corner regions. In the case of two fully independent hypotheses tested in two
separate trials, the FMER is 4 ∗ 0.025ଶ = 0.0025. Therefore FWER + FMER is 0.1, as
expected.
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Note that the FMER is directly related to the conditional probability of a type-I error
ܲ(ܪ଴஻|ܪ଴஺), as discussed in Section 3.1, since:
ܲ(ܪ଴஻|ܪ଴஺) = ܲ(ܪ଴஺ ∩ ܪ଴஻)ܲ(ܪ଴஺)
However, the FMER is easier to interpret in the case of a multi-arm trial due to the
hypotheses not necessarily having any sensible order.
Multiple Superior False Positives (MSFP):
In figure 2, the lower left corner signifies both false positives falling in the rejection
region in favour of the control, thus declaring the experimental treatment significantly
inferior (multiple inferior false positive outcomes), the upper right corner signifies both
false positives falling in favour of the experimental treatments (multiple superior false
positive (MSFP) outcomes), and the upper left and lower right corners signify one false
positive favouring the control and the other an experimental treatment. The chance of
MSFP errors could be important if the outcomes of the hypotheses inform a single claim
of effectiveness, as discussed in Section 6. In the independent case with two hypotheses,
the probability of a MSFP outcome is 0.0252 = 0.000625.
4.2 The effect of positive correlation due to the shared control group
19
Recall Figure 1b illustrating a typical three-arm trial design with two experimental
arms, A and B, and a shared control group Z. Since both treatments are being compared
to the same control data, the comparisons are not independent. That is, if the control
group sample, by chance, perform worse than the true population, there is an increased
probability that both therapies A and B will report a false positive outcome to conclude
that they are superior. The test statistics are therefore positively correlated, since the
outcomes for the control sample will affect both in the same way.
It has previously been shown that the positive correlation between the test statistics
reduces the probability of making at least one type-I error (the FWER) over cases where
there is no correlation, such as in independent trials; but the probability of making two
or more errors is higher, such that “the conditional probability of a Type-I error on one
comparison with control, given that a Type-I error has been made on another
comparison with control, is substantially increased” in the correlated case15, 16. We
further quantify and expand on these findings in order to inform recommendations on
the need for a multiple testing adjustment in multi-arm trials with correlated test
statistics.
4.3 Calculating the correlation between the test statistics due to sharing control data
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Recall from Section 4.1 that in the case of multi-arm trials with independent
experimental therapies and a shared control group, the test statistics for the
comparisons, ஺ܺ and ܺ஻, can be assumed to follow standardised normal distributions
when sample sizes are reasonable. Their joint distribution therefore follows a
standardised bivariate normal with correlation ߩ஺஻ . Relevant theory is given in
Follmann et al.18.
Dunnett19 notes that the correlation between the test statistics is directly linked to the
allocation ratio, as follows:
ߩ஺஻ = 1
ටቀ ௓݊
஺݊
+ 1ቁቀ ௭݊
஻݊
+ 1ቁ
where ௜݊ is the sample size in group i (i = A, B, Z).
If the allocation ratio is 1:1:1, the correlation is 0.5. For an allocation of 2:1:1 in favour
of control, the correlation is 0.333. With 1:2:2, the correlation is 0.667.
4.4 Calculating the FWER, FMER and MSFP assuming a multivariate normal
distribution, incorporating correlation
21
The various false positive errors of potential interest in a multi-arm trial can be
calculated based on the assumption of the joint distribution of the test statistics
following a standardised multivariate normal distribution. The R program in Appendix
1 computes these probabilities in the case of two or three experimental therapies,
allowing varying correlation, in order to calculate the error density in each of the
rejection regions.
The effect of the correlation on the rejection regions in the case of two experimental
treatments is illustrated in figure 3. As the correlation increases, the proportion of error
in the lower left and upper right corners, indicating false positive outcomes in the same
direction for both hypotheses, also increases. That is, if the shared control group
performs better or worse than expected, there is a greater chance of an error in both of
the hypotheses in the same direction, as expected. The effect of this correlation on the
different types of errors described in Section 4.1 can easily be calculated by solving the
probabilities of the outcomes falling within the relevant rejection regions.
[Insert Figure 3]
Figure 3. Illustration of rejection regions for:
a) two hypotheses, each with individual control data, ρ=0 
b) two hypotheses with shared control data and 2:1:1 randomisation, ρ=0.333 
22
c) two hypotheses with shared control data and 1:1:1 randomisation, ρ=0.5 
d) two hypotheses with shared control data and 1:2:2 randomisation, ρ=0.667 
4.5 FWER, FMER and MSFP comparison for multi-arm trials with a shared control
group compared to independent trials
The R program in Appendix 1a can be used to calculate the FWER, FMER and MSFP
rates for different levels of correlation based on the allocation ratio in three-arm trials
with two experimental arms and a shared control. The code has also been extended to
calculate the probabilities for four-arm trials with three experimental arms and a shared
control, provided in Appendix 1b. These probabilities are shown in table 1.
Independent
case
(Separate
trials)
Dependent
case
2:1:1(:1)
(2 to control)
Dependent
case
1:1:1(:1)
Dependent
case
1:2:2(:2)
(1 to control)
Correlation (ρ) 0 0.333 0.5 0.667
Reject H0 for each
individual
hypothesis (A, B or
C)
0.050 0.050 0.050 0.050
Three-arm trial (hypotheses A and B)
FWER: Reject at
least one H0, A or
B
0.0975 0.0946 0.0908 0.0849
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FMER: Reject
both H0’s A and B
(in any direction)
0.0025 0.0054 0.0093 0.0151
MSFP: Reject both
H0’s in favour of
treatments A and B
0.00063 0.00267 0.00462 0.00753
Four-arm trial (hypotheses A, B and C)
FWER: Reject at
least one H0, A, B
or C
0.1426 0.1348 0.1254 0.1124
FMER2: Reject at
least two H0’s (in
any direction)
0.0072 0.0141 0.0214 0.0301
FMER3: Reject all
three H0’s A, B and
C (in any direction)
0.0001 0.0011 0.0032 0.0076
MSFP2: Reject at
least two H0’s in
favour of A, B or C
0.0018 0.0069 0.0107 0.0150
MSFP3: Reject all
three H0’s in
favour of A, B and
C
0.00002 0.00056 0.00160 0.00378
Table 1. FWER, FMER and MSFP comparisons for three and four arm trials with a
shared control group and varying allocation ratios, compared to independent 1:1
randomised trials (α=0.05 for each hypothesis) 
FWER:
The FWER is lower in all cases with shared control data than the equivalent error when
assessing two independent trials. That is, the correlation between the test statistics
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reduces the overall probability of a type-I error occurring across either of the hypotheses
over the case where there is no shared control data, as also shown by Proschan et al.15.
FMER:
In a multi-arm trial with two hypotheses, the chance of multiple errors has increased
from 0.25% for independent trials to 0.93% in the case with even allocation, an increase
of 3.7 times. The message stays the same as the number of hypotheses increases; in the
case with three hypotheses and even allocation, the chance of any two errors is now
over 2%, which is not trivial. Similar increases are found with unequal allocation ratios
and the trend across the resultant correlations from these changing allocation ratios can
be clearly seen.
The increase in the FMER is due to the increased chance of an error occurring within
the correlated comparisons in the same direction. This is caused by a chance deviation
in the outcome for the control sample from the outcome for the true population. The
probability of multiple type-I errors in opposite directions has decreased, as expected
from figure 3, but to a lesser extent than the increase in the chance of errors in the same
direction. Recall that the total error (FWER + FMER) is fixed, thus the increased FMER
explains the reduction in the FWER.
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MSFP:
With two hypotheses, the MSFP rate has increased from 0.06% in independent trials to
0.46% in the multi-arm case with even allocation, an increase of 7.7 times. With three
hypotheses, the chance of any two superior false positive outcomes has increased by
nearly 6 times to over 1%, and the chance of three MSFPs is substantially greater than
in the independent case, although the probability is very small at 0.16%. Again, similar
patterns and trends are seen for other allocation ratios. This is intuitively obvious since a
chance ‘bad’ outcome in the control sample compared to the true population would
increase the chances of false positives in both hypotheses, but the magnitude of this
effect is now apparent, and is not trivial.
5. An investigation of the effect of multiplicity adjustment methods
Many multiplicity adjustment procedures have been devised to strongly control the
FWER for a number of tests within a family of hypotheses. The adjustment methods
considered here are: Bonferroni20, a simple, conservative and popular adjustment
method; Holm21 and Hochberg22, closed testing methods based on a hierarchical
strategy of testing the outcomes ordered by significance; Dunnett’s t19, a parametric
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method that adjusts the Bonferroni boundaries to control the probability of observing a
significant result under H0 at 0.05; and Dunnett and Tamhane23, an adjusted Hochberg
step-up multiple test procedure in which the rejection levels are adjusted to account for
the correlation so that the final FWER is 0.05.
Table 2 shows the effects of applying these adjustment methods on the various error
rates, using the example of a three arm trial with 1:1:1 allocation ratio in which the two
experimental arms are compared to a shared control group.
Independent
case
Dependent case, 1:1:1 allocation
Un-
adjusted
Bonferro
ni
Holm Hochberg Dunnett’s
t
Adjusted
Hochberg
Reject H0 for
individual
comparison
(A or B)
0.0500 0.0500 0.0250 0.0271 0.0286 0.0271 0.0296
FWER:
Reject at least
one H0, A or
B
0.0975 0.0908 0.0465 0.0465 0.0480 0.0502 0.0500
FMER:
Reject both
H0’s A and B
(in any
direction)
0.0025 0.0093 0.0035 0.0077 0.0093 0.0039 0.0093
MSFP: Reject
both H0’s in
favour of
treatments A
and B
0.00063 0.00462 0.00176 0.00385 0.00462 0.00197 0.00462
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Table 2. FWER, FMER and MSFP comparisons for three arm trials with two
hypotheses (α=0.05 for each), a shared control group and even allocation ratio, after 
applying various multiple testing adjustments
FWER:
All adjustment methods control the FWER at 0.05 or less, as expected. In all cases, the
chance of rejecting the null hypothesis for each individual comparison has taken a
penalty compared to running independent trials. The Dunnett’s t and Adjusted
Hochberg methods account for the effect of the correlation due to the shared control
data on the FWER, in order to make less conservative adjustments than the other
methods.
FMER:
Although adjustment methods control the probability of falsely rejecting at least one
hypothesis, no method fully controls the chance of multiple errors occurring within the
same set of hypotheses to be what it would have been if the hypotheses had been
assessed in independent trials.
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With Bonferroni and Dunnett’s t, the probabilities of multiple errors are reduced
towards those in independent trials, but the Holm, Hochberg and Adjusted Hochberg
methods based on the closed testing principle offer very little or no protection of the
FMER over no adjustment. The first step of a step-up procedure is to accept all
hypotheses if the least significant is <0.05, so it can easily be seen why this is the case.
Intuitively, if the critical level is set lower, as with the Bonferroni method, fewer null
hypotheses will be rejected in all comparisons, and therefore the chance of both being
rejected will also decrease. However, since a ‘bad’ outcome in the shared control
sample would still affect both comparisons by increasing the chances of a false positive
error, it makes sense that a higher proportion of paired hypotheses are both rejected
when they share a common control.
MSFP:
Since the adjustment methods do not control the FMER, they also do not offer full
protection against the chance of MSFP outcomes. After applying the Bonferroni and
Dunnett’s t corrections, the chance of two superior false positive errors is still inflated
by approximately 3 times over that with independent trials, and following the Hochberg
adjustments this rises to over 7 times.
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The above results highlight that multiple testing adjustment methods only control the
probability of the overall FWER to that for a single hypothesis. They do not offer
control over the chance of multiple false positive errors, which is the probability that is
increased over that had the hypotheses been assessed in independent trials.
6. Controlling the probability of multiple superior false positive outcomes
We have shown that in the case where two superior hypotheses may both be used to
jointly inform a claim of effectiveness, the overall chance of both having a false positive
outcome in favour of the experimental treatments (MSFP) is inflated in a multi-arm trial
over that chance occurring in independent trials. In addition, applying multiple testing
correction methods do not reduce the chance of MSFP outcomes to the same level as in
two independent trials.
The FDA guidance on ‘Providing Clinical Evidence of Effectiveness for Human Drug
and Biological Products’24 suggests that it is feasible for multiple hypotheses from
within a single study to be accepted as evidence of effectiveness if the trial is designed
appropriately. In this case, it would be important that the probability of multiple
conclusions of superiority (MSFP) is not inflated over that for independent studies. The
example of the AMAGINE-1 trial described in Section 2.2 assesses two doses of an
experimental treatment against placebo. If these doses were investigated in independent
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trials, both trial outcomes may be used to inform a claim of effectiveness, but the
penalty for assessing these within a multi-arm trial in terms of inflation of the MSFP
rate has not been investigated or quantified. This is a similar issue to that discussed by
Shun et al25, in which they require the overall ‘positive rejection region’ in a large
pivotal trial to be controlled to the same level as in two smaller pivotal trials.
6.1 Critical values to control the MSFP rate in the case of three arms
In two independent trials, the chance of two superior false positive outcomes is
0.000625 (Section 4.1). Since the joint distribution can be described using a bivariate
normal (Section 4.4), this can be used to obtain the exact critical value that returns a
probability of 0.000625. This principle is similar to the work of Follmann et al., which
relies on the multivariate normal assumption of the test statistics to estimate critical
values that strongly protect the type-I error rate in the case of multi-armed trials with
interim looks18. The R code to calculate the critical value is provided in Appendix 2.
In the 1:1:1 case, the critical value required to protect the MSFP rate at 0.000625 is
0.0118. In the 2:1:1 case it is 0.0195, and in the 1:2:2 case it is 0.0069, as shown in
Table 3. That is, if two hypotheses are assessed in a multi-arm trial with a shared
control group, and are to be used to jointly inform a claim of effectiveness; in order to
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control the probability of two superior false positive outcomes to the level in
independent trials, the p-values for both hypotheses are required to be less than these
adjusted critical values. It can be seen that with this level of control, the FWER is
reduced to much lower than 5%.
Independent case
No adjustment
Dependent
case
No
adjustment
Dependent
case 2:1:1
α = 0.0195 
Dependent
case 1:1:1
α = 0.0118 
Dependent
case 1:2:2
α = 0.0069 
Reject H0 for
individual
comparison (A
or B)
0.050 0.050 0.0195 0.0118 0.0069
FWER: Reject
at least one H0,
A or B
0.0975 0.0908 0.0377 0.0224 0.0125
MSFP: Reject
both H0’s in
favour of
treatments A
and B
0.000625 0.00462 0.000623 0.000624 0.000628
Table 3. Adjusted critical values to control the chance of a MSFP error in a three-arm
trial to that for two independent 1:1 randomised trials
6.2 The effect of MSFP control on the power and sample size
If a trial is designed to allow two superior outcomes to be used as evidence to inform a
single claim of effectiveness, the power is required to be maintained for each hypothesis
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as it would for independent trials, requiring an increased sample size. As an example,
take a confirmatory trial with a survival primary endpoint and analysis based on the log-
rank test for equality based on an exponential survival distribution. Assume that the
estimated median survival in the control group is 36 months, and that a clinically
relevant difference would be an improvement to 48 months (HR=0.75). In a two-arm
trial, with a recruitment period of 48 months and an additional 36 month follow-up
period, 408 patients are required per arm (1:1) to achieve 508 events for 90% power
with a type-I error rate of 5%.
If there are two experimental arms of interest in the population, a three-arm trial may be
considered rather than two independent trials. In the scenario of running independent
trials, the total sample size for the two trials assuming 1:1 allocations would be 1632,
and in the multi-arm trial this is reduced to 1224 with no adjustment. Adjusting to
control the chance of MSFP outcomes reduces the power from 90% to 77%, and to
account for this loss in power the sample size would need to be increased by 37% to
1680, which makes the multi-arm trial slightly larger than running two independent
trials. There may still be benefits of running a multi-arm trial, however, in terms of
reducing the total number of patients receiving the control therapy as well as the time
and cost of only needing to set-up and run a single trial.
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7. Discussion
Multi-arm trials can be efficient and therefore advantageous over running independent
trials. However, there are conflicting views in the literature on how to appropriately
control the probability of a false positive error. A lack of proper control of the FWER
could lead to an unacceptable chance of an ineffective treatment being recommended to
be taken forward into practice; but unnecessary control of the FWER could affect the
efficiency of a trial, requiring increased patient numbers and resources. FWER
adjustment without increasing the sample size to maintain power could lead to a
superior treatment being denied. Each of these scenarios raises ethical concerns.
False positive error rates may be affected in multi-arm trials compared to independent
trials due to either: correlation between the comparisons caused by the shared use of the
control data; or an increased chance of making a claim of effectiveness because of an
increased ability to test a family of hypotheses. It is a common misconception that
FWER adjustment is necessary due to sharing control data. When considering the
designs illustrated in Figures 1a and 1b, some might assume that the overall FWER for
the family of hypotheses, H0A and H0B, would be larger in Figure 1b where there is a
common control group. However, we have confirmed that the FWER is in fact smaller
in Figure 1b than in Figure 1a. The common control group instead has the effect of
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increasing the chances of more than one false positive outcome within the family of
hypotheses; although FWER adjustment methods do not control for this. The necessity
for a FWER adjustment is therefore only dependent on whether assessing multiple
hypotheses within a multi-arm trial has increased the chance of making a single claim of
effectiveness.
We have formalised the implications of running a multi-arm trial with shared control
data on the probabilities of various types of false positive errors, considering the effects
of multiple testing adjustment methods on these probabilities, in order to make informed
recommendations on the requirement for adjustment. The findings are summarised
below. In addition, a flow diagram to aid the determination of the requirement for a
multiple testing adjustment in a multi-arm trial is provided in Figure 4. Note that the
decisions on the need for error control with respect to the interpretation of the trial
results should be agreed and documented in advance in the protocol and statistical
analysis plan.
[Insert Figure 4]
Figure 4. Decision diagram to determine the requirement for a multiple testing
adjustment in multi-arm trials
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7.1 Familywise Error Rate (FWER) in the case where each hypothesis informs a
different claim of effectiveness
Consider the case in which multiple hypotheses are being assessed in the same trial with
a shared control group, but each hypothesis informs a different claim of effectiveness.
An obvious example is where the experimental arms assess entirely different therapies.
A further example is the MRC COIN trial12 introduced in Section 2.1. OxFP is present
in all treatment arms, however since one primary hypothesis addresses the addition of
an experimental therapy to OxFP and the other addresses a reduction in duration of
OxFP therapy, these do not contribute towards the same claim of effectiveness. In this
case, the chance of a false positive outcome for either claim of effectiveness is not
increased by the presence of the other hypothesis.
Since we have confirmed that the correlation between comparisons due to the shared
control data has the effect of reducing the overall chance of at least one false positive
finding (FWER) over that chance had the same questions been asked in independent
hypothesis tests, FWER adjustment is not necessary due to the shared control sample.
These findings remain valid in the case of imbalanced randomisations, and also where
there are more than two experimental therapies.
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Therefore, adjusting to control the FWER in this case is an unnecessary penalty. It does
not make sense here to consider the type-I error rate for the trial as a whole since any
claim of effectiveness is only informed by a single hypothesis test. Note that if the
experimental therapies are competing against each other for approval in the trial
population, the correlation due to the shared control group is an advantage. If in two
independent trials one of the control samples performs worse than the true population,
the associated experimental group has an increased chance of being significant and
taken forward. However, in the equivalent multi-arm case, bias due to comparisons to
different control samples is removed. It is more likely that efficacious experimental
therapies would be considered against each other directly without the influence of
variations in the control samples.
7.2 Familywise Error Rate (FWER) in the case where the hypotheses inform a single
claim of effectiveness
We have shown that the FWER is not inflated due to running a multi-arm trial with a
shared control group. However, it should be noted that FWER adjustment may be
required if the efficiency of running a multi-arm trial leads to more hypotheses being
included than would have otherwise been assessed in independent trials. If these
hypotheses inform the same claim of effectiveness, for example if the experimental
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arms assess different doses or combinations of the same experimental therapy, the
overall chance of a false positive result anywhere within the family of hypotheses is
clearly increased over that for a single hypothesis. In this case, there is general
agreement in the literature that FWER control is recommended7 since the type-I error
rate can be considered for the claim of effectiveness as a whole, rather than for each
individual hypothesis. Note that it also follows that the power in this case can be
considered to be the overall chance of observing at least one true positive outcome, and
this will also be increased by testing multiple hypotheses. Therefore, the penalty caused
by applying the FWER adjustment may be compensated to some extent by the gain in
overall power.
An example here is the AMAGINE-1 trial (Section 2.2) assessing two doses of
brodalumab compared to placebo. Since a rejection of the primary hypotheses for each
comparison could lead to a claim of effectiveness for brodalumab, there are two chances
for a false positive result with respect to that claim, and therefore FWER adjustment is
recommended.
7.3 Familywise Error Rate (FWER) in the case where all hypotheses are required to
have superior outcomes in order to make a claim of effectiveness
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If all trial hypotheses are required to be positive in order to make a claim of
effectiveness, there is essentially only one overarching hypothesis being tested. In this
case, there is only one chance for an overall false positive outcome for the trial, so the
chance of ‘at least one’ error cannot be inflated, and therefore no FWER adjustment is
necessary.
For example, the Myeloma XI+ Intensive trial (Section 2.3) compared the four-drug
regime CCRD against the current standard control CTD, as well as the previously
assessed three-drug regime CRD (which is CCRD excluding carfilzomib). Since CCRD
will only be recommended for approval if it is better than both CTD and CRD, both
hypotheses are required to be significant in order to recommend CCRD for use in
practice. In this case, no adjustment is required.
7.4 Multiple Superior False Positives (MSFP) in the case where multiple superior
outcomes could be used as separate pieces of evidence towards a single claim of
effectiveness
In Section 7.2 we discuss the case where multiple hypotheses are being assessed in the
same trial with a shared control group, with each hypothesis being tested and reported
individually. If superiority in more than one of these hypotheses could contribute as
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separate pieces of evidence towards a claim of effectiveness for a therapy, a more
stringent adjustment is required for the evidence to be equivalent to that obtained from
two independent trials, as discussed in Section 6.
We have shown that the correlation due to the shared control group increases the chance
of falsely declaring more than one experimental treatment group to be superior to the
shared control group (MSFP) in a multi-arm trial over that chance had the hypotheses
been assessed in independent trials. Standard multiple testing adjustment methods do
not adequately control for this. We have proposed a critical value adjustment to control
the chance of MSFP outcomes in a three-arm trial in order for the evidence to be
equivalent to that obtained from two independent trials.
Care should always be taken in reporting and interpretation if more than one hypothesis
within a multi-arm trial with shared control group is positive.
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Appendix 1a: R code to calculate the probabilities for the rejection regions based
on two correlated comparisons, assuming a bivariate normal distribution.
#Install library first use
setInternet2(TRUE)
install.packages("mvtnorm")
library(mvtnorm)
#Bivariate normal case (2 experimental arms)
#set correlation
corr <- 0
#correlation matrix
corrmat <- matrix(c(1,corr,corr,1),ncol=2,byrow=TRUE)
#Exactly 1 error (calculate probabilities for the edges
#excluding the corners of the square)
# Left hand side
leftside <- pmvnorm(lower=c(-Inf,-1.96), upper=c(-1.96,1.96), corr =
corrmat )
# Right hand side
rightside <- pmvnorm(lower=c(1.96,-1.96), upper=c(Inf,1.96), corr =
corrmat )
# Top edge
topside <- pmvnorm(lower=c(-1.96,1.96), upper=c(1.96,Inf), corr =
corrmat )
# Bottom edge
bottomside <- pmvnorm(lower=c(-1.96,-Inf), upper=c(1.96,-1.96), corr =
corrmat )
# Total chance of exactly 1 error
oneonly=leftside+rightside+topside+bottomside
#Exactly 2 errors (calculate probabilities in each of the 4 corners of
the square)
# Lower left corner
lowleft <- pmvnorm(lower=c(-Inf,-Inf), upper=c(-1.96,-1.96), corr =
corrmat )
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# Lower right corner
lowright <- pmvnorm(lower=c(1.96,-Inf), upper=c(Inf,-1.96), corr =
corrmat )
# Upper Left corner
upleft <- pmvnorm(lower=c(-Inf,1.96), upper=c(-1.96,Inf), corr =
corrmat )
# Upper Right corner
upright <- pmvnorm(lower=c(1.96,1.96), upper=c(Inf,Inf), corr =
corrmat )
# Total chance of exactly 2 errors
twoonly <- lowleft+lowright+upleft+upright
# FWER
FWER <- oneonly+twoonly
# Probability of any two errors (FMER)
FMER <- twoonly
# MSFP probability of two superior false positives
MSFP <- upright
#Output results
corrmat
FWER
FMER
MSFP
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Appendix 1b: R code to calculate the probabilities for the rejection regions based
on three correlated comparisons, assuming a trivariate normal distribution.
# Install library first use
setInternet2(TRUE)
install.packages("mvtnorm")
library(mvtnorm)
# Trivariate normal case (3 experimental arms)
#set correlation
corr <- 0.5
#correlation matrix
corrmat <-
matrix(c(1,corr,corr,corr,1,corr,corr,corr,1),ncol=3,byrow=TRUE)
#Exactly 1 error (illustrated by the 6 side face of a cube minus the
upper and lower 5% around the edges)
Oneonly1 <- pmvnorm(lower=c(-1.96,-1.96,-Inf), upper=c(1.96,1.96,-
1.96), corr = corrmat )
Oneonly2 <- pmvnorm(lower=c(-1.96,-1.96,1.96), upper=c(1.96,1.96,Inf),
corr = corrmat )
Oneonly3 <- pmvnorm(lower=c(-Inf,-1.96,-1.96), upper=c(-
1.96,1.96,1.96), corr = corrmat )
Oneonly4 <- pmvnorm(lower=c(1.96,-1.96,-1.96), upper=c(Inf,1.96,1.96),
corr = corrmat )
Oneonly5 <- pmvnorm(lower=c(-1.96,-Inf,-1.96), upper=c(1.96,-
1.96,1.96), corr = corrmat )
Oneonly6 <- pmvnorm(lower=c(-1.96,1.96,-1.96), upper=c(1.96,Inf,1.96),
corr = corrmat )
# Total chance of exactly 1 error
Oneonly=Oneonly1+Oneonly2+Oneonly3+Oneonly4+Oneonly5+Oneonly6
#Exactly 2 errors (illustrated by the 12 edges of a cube minus the
upper and lower 5% in the corners)
# the 3 edges that corner the triple rejection in favour of control
(lower left front)
onlyllx <- pmvnorm(lower=c(-1.96,-Inf,-Inf), upper=c(1.96,-1.96,-
1.96), corr = corrmat )
onlylly <- pmvnorm(lower=c(-Inf,-1.96,-Inf), upper=c(-1.96,1.96,-
1.96), corr = corrmat )
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onlyllz <- pmvnorm(lower=c(-Inf,-Inf,-1.96), upper=c(-1.96,-
1.96,1.96), corr = corrmat )
# the 3 edges that corner the triple rejection in favour of the
experimental arms (upper right back)
onlyurx <- pmvnorm(lower=c(-1.96,1.96,1.96), upper=c(1.96,Inf,Inf),
corr = corrmat )
onlyury <- pmvnorm(lower=c(1.96,-1.96,1.96), upper=c(Inf,1.96,Inf),
corr = corrmat )
onlyurz <- pmvnorm(lower=c(1.96,1.96,-1.96), upper=c(Inf,Inf,1.96),
corr = corrmat )
#Off edges (l=lower u=upper f=front b=back l=left r=right):
onlylrz <- pmvnorm(lower=c(1.96,-Inf,-1.96), upper=c(Inf,-1.96,1.96),
corr = corrmat )
onlyfry <- pmvnorm(lower=c(1.96,-1.96,-Inf), upper=c(Inf,1.96,-1.96),
corr = corrmat )
onlylbx <- pmvnorm(lower=c(-1.96,-Inf,1.96), upper=c(1.96,-1.96,Inf),
corr = corrmat )
onlyufx <- pmvnorm(lower=c(-1.96,1.96,-Inf), upper=c(1.96,Inf,-1.96),
corr = corrmat )
onlyulz <- pmvnorm(lower=c(-Inf,1.96,-1.96), upper=c(-1.96,Inf,1.96),
corr = corrmat )
onlybly <- pmvnorm(lower=c(-Inf,-1.96,1.96), upper=c(-1.96,1.96,Inf),
corr = corrmat )
# Total chance of exactly 2 errors
Twoonly <-
onlyllx+onlylly+onlyllz+onlyurx+onlyury+onlyurz+onlylrz+onlyfry+onlylb
x+onlyufx+onlyulz+onlybly
# Exactly 3 errors (Calculate probabilities in each of the 8 corners
of a cube)
x1y1z1 <- pmvnorm(lower=c(-Inf,-Inf,-Inf), upper=c(-1.96,-1.96,-1.96),
corr = corrmat )
x2y1z1 <- pmvnorm(lower=c(1.96,-Inf,-Inf), upper=c(Inf,-1.96,-1.96),
corr = corrmat )
x1y2z1 <- pmvnorm(lower=c(-Inf,1.96,-Inf), upper=c(-1.96,Inf,-1.96),
corr = corrmat )
x1y1z2 <- pmvnorm(lower=c(-Inf,-Inf,1.96), upper=c(-1.96,-1.96,Inf),
corr = corrmat )
x2y2z1 <- pmvnorm(lower=c(1.96,1.96,-Inf), upper=c(Inf,Inf,-1.96),
corr = corrmat )
x2y1z2 <- pmvnorm(lower=c(1.96,-Inf,1.96), upper=c(Inf,-1.96,Inf),
corr = corrmat )
x1y2z2 <- pmvnorm(lower=c(-Inf,1.96,1.96), upper=c(-1.96,Inf,Inf),
corr = corrmat )
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x2y2z2 <- pmvnorm(lower=c(1.96,1.96,1.96), upper=c(Inf,Inf,Inf), corr
= corrmat )
# Total chance of exactly 3 errors
Threeonly <- x1y1z1+x2y1z1+x1y2z1+x1y1z2+x2y2z1+x2y1z2+x1y2z2+x2y2z2
#FWER – the overall error region of the sides, edges and corners
FWER=Oneonly+Twoonly+Threeonly
# Probability of at least any two errors
twoerr <- Twoonly+Threeonly
# Probability of three errors - sum of the corner regions
threeerr <- Threeonly
# Two MSFP - probability of at least two superior false positives
# Sum of the 3 edges meeting the upper right back
#(i.e. two false positives along the plane of the third distribution)
# and the upper right corner
TwoMSFP <- onlyurx+onlyury+onlyurz+x2y2z2
# Three MSFP - probability of three positive false positives
ThreeMSFP <- x2y2z2
#Output results
corrmat
FWER
twoerr
threeerr
TwoMSFP
ThreeMSFP
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Appendix 2: R code to calculate the rejection region required to control the
probability of two MSFP errors based on correlated comparisons to that for
independent trials, assuming a multivariate normal distribution.
# Install library first use
setInternet2(TRUE)
install.packages("mvtnorm")
library(mvtnorm)
#The MSFP is the upper right corner of the rejection regions in
#figure 2 (based on the standardised bivariate normal).
#The MSFP needs to be controlled at 0.000625 (0.025**2)
#set correlation
corr <- 0.5
#correlation matrix
corrmat <- matrix(c(1,corr,corr,1),ncol=2,byrow=TRUE)
#Solve the critical value for the upper right corner
#equalling 0.000625
upperx <- qmvnorm(p=0.000625,tail=c("upper.tail"),corr=corrmat)
uppertail <- upperx$quantile
adjcval <- 2*(1-pnorm(uppertail))
adjcval
